AX 202
Alternative Names: AX-202Latest Information Update: 25 Jan 2024
Price :
$50 *
At a glance
- Originator Arxx Therapeutics
- Developer Calluna Pharma
- Class Antifibrotics; Antipsoriatics; Monoclonal antibodies
- Mechanism of Action S100 calcium-binding protein A4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Plaque psoriasis
- Preclinical Systemic scleroderma
- Research Unspecified